Trevi Therapeutics announced that results from its Phase 2b CORAL trial of oral nalbuphine ER, a treatment for chronic cough in idiopathic pulmonary fibrosis (IPF) patients, will be presented at the CHEST 2026 Annual Meeting. The trial showed early and sustained improvements in patient-reported outcomes and a significant reduction in cough frequency. This therapy addresses a high unmet need as there are no FDA-approved treatments for chronic cough in IPF and related lung diseases. The presentation will be delivered by Dr. Philip Molyneaux on October 20, 2026, highlighting the potential of nalbuphine ER to improve quality of life in affected patients.
Trevi Therapeutics' oral nalbuphine ER trial results are set for presentation at CHEST 2026. For readers following the health sector, here is Pluang's market snapshot as of Oct 13, 2026 18:02 WIB: out of 128 priced US health stocks, 78 rose and 41 fell. Notable movers include LFST at USD 12.69 (+1.68%), NBIX at USD 139.05 (-1.64%), and SNY at USD 40.37 (+1.59%).
Existing-home sales in the U.S. increased by 1.5% month-over-month in September but declined 2.2% compared to the previous year, according to the National Association of Realtors. Sales rose in the South and West regions but fell in the Northeast and...
Columbus Marketing Experts, a digital marketing agency in Hilliard, Ohio, is expanding its local SEO services across Columbus to help service businesses improve their visibility on Google Search and Google Maps. The expansion aims to enhance local di...
Schrödinger's stock fell 5.02% to $25.91 despite co-founding Tectora, a new biopharma venture with $55 million funding targeting immune and inflammatory treatments. The company, known for its molecular modeling software, holds a market value of about...
Johnson & Johnson reported third-quarter 2026 earnings per share of $2.59, surpassing analyst estimates of $2.52, with total revenue of $25.40 billion slightly above expectations. The company saw robust growth in its pharmaceutical segment, which off...
Nvidia CEO Jensen Huang has reaffirmed his forecast that global spending on AI infrastructure will grow significantly, reaching between $3 trillion and $4 trillion by 2030. This projection highlights the massive potential and ongoing investment in AI...
